SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors react to a new federal initiative that pairs the company with major technology firms to accelerate the deployment of advanced nuclear reactors for AI data centers. While the community remains divided between long-term optimism over these commercial partnerships and skepticism regarding the timeline for achieving reactor criticality and the recurring stock sales by company insiders.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is attracting significant attention as investors react to exceptional financial performance, raised profit guidance, and growing momentum in its Small Modular Reactor and defense segments. Community sentiment is largely bullish, with active discussions focused on the company's expanding order pipeline, hyperscaler data center partnerships, and its role in sovereign defense programs.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors monitor the company's efforts to secure European regulatory approval for Miplyffa while evaluating the long-term impact of its patent exclusivity and growth in U.S. patient reach. Market sentiment remains focused on the potential catalyst of an EMA decision, with ongoing discussions centered on institutional confidence, stock volatility, and the company's valuation relative to its rare disease portfolio.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano (ADA) is currently trending amid heightened community debate regarding its long-term viability and recent price action, with some investors viewing the current levels as a deep-value accumulation opportunity while others express significant frustration over stalled growth and leadership dynamics. Discussions are heavily focused on potential catalysts like the Clarity Act and network upgrades, set against a backdrop of broad uncertainty across the altcoin sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing intense community engagement as investors eagerly anticipate the Phase 3 IZAR-1 clinical trial readout, which is widely considered a major catalyst for the company. While the stock's price action remains volatile and subject to short-term pressure, the community is actively debating the timing of the data release and the potential for a significant valuation re-rating driven by the drug's best-in-class efficacy potential.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing intense community debate, fueled by sharp criticism over its multi-year underperformance and active rebalancing strategy compared to passive benchmarks. While some investors remain skeptical of Cathie Woods conviction-based approach, others are closely monitoring her recent accumulation of AI and space-related holdings as potential entry points in a volatile market.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is facing increased scrutiny following reports of a treasury exploit that drained millions in tokens, fueling intense community debate over security and long-term viability. While some investors view the volatility as a potential accumulation opportunity, many others are expressing frustration over the decline and questioning the lack of clear communication regarding the project's future.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong fundamental growth and surging international LNG prices against ongoing geopolitical turmoil in the Middle East and concerns over regional supply chain disruptions. Community discussions are heavily focused on the disconnect between the company's robust export capacity and its recent share price volatility, with many users highlighting the strategic advantage of its long-term take-or-pay contracts amid global energy shortages.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is currently being driven by a tug-of-war between aggressive AI infrastructure spending and heightened geopolitical tensions in the Middle East. Community sentiment remains polarized, with many traders actively debating whether to scale back leveraged positions due to volatility or to continue buying dips under the belief that AI fundamentals will ultimately outweigh macro headwinds.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is seeing heightened investor attention as market participants debate the role of small modular reactors in meeting the massive energy demands of AI data centers. While community members remain divided over the company's timeline for commercial contracts and management execution, the stock continues to trade with significant volatility alongside broader nuclear sector trends and interest in clean energy infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?

Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential...

What is HC Wainwright's Forecast for BBOT FY2026 Earnings?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report) - HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of BridgeBio Oncology Therapeutics in a report issued...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low - Here's Why...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Here's What Happened

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Up 4.9% - Still a Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 5.8% - What's Next...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Large Volume Increase  - Still a Buy?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sees Strong Trading Volume - Time to Buy...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - What's Next?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 6.8% - Time to Sell...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 12-Month Low - Here's What Happened...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 1.3% - Should You Sell...

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BridgeBio Oncology Therapeutics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.09
Prev Close	$8.50
Open	$8.50
Dividend Yield	0.00%
50-Day Moving Average	$8.21
Beta	2.00
Avg. Volume	482,216.65
PE Ratio	-0.02

52-Week High	$14.87
52-Week Low	$7.00
Market Capitalization	$648.07M
EPS (Annual)	-$4.30
Price to Book	1.74
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info